WillItSurvive
Medical technology and health companies · subsidiary of Abbott Laboratories · United States

Exact Sciences

exactsciences.com ↗

Maker of Cologuard, the at-home colon cancer screening test, now an Abbott subsidiary.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from October 2026 · Every call on the record Checkpoint: Abbott Q3 2026 earnings: check if Cologuard holds mid-teens growth and second-half acceleration
The call

Cologuard's regulatory and reimbursement standing looks solid, but the company's near-term story now runs through Abbott's balance sheet and integration choices.

Exact Sciences makes Cologuard, a mail-in colon cancer screening test that doctors order for patients. The test is hard to copy because it took years of clinical trials to prove it works, and the FDA approved it based on that evidence, no AI company can skip those steps or build a competing test quickly. Abbott bought the company in early 2026, which protects Cologuard from traditional rivals but creates a new risk: Abbott is now loaded with debt from the purchase and has cut its profit guidance, so it may not fund new products or keep all the current staff. The key question is whether Cologuard keeps growing at mid-teens rates through the rest of 2026 under Abbott's ownership, and whether the integration goes smoothly enough to avoid losing key people.

Why
01
AI pressure: None apparent. AI reads Cologuard's lab data internally to call results, it does not replace the FDA-cleared test or its billing codes. Could AI do the core job? Unlikely.
02
Bigger players: Guardant Health (Shield blood test) and GRAIL (Galleri/PATHFINDER 2). Blood-based screening rivals are pushing for coverage parity, but Cologuard still keeps far more volume and reimbursement history. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of clinical trial data, CMS/insurer coverage, and doctor habit around Cologuard, now backed by Abbott's sales scale.
What would change this call
Abbott Q3 2026 earnings (~October 2026) Cologuard growth rate reported. Shows whether mid-teens growth and stronger-second-half model are holding under Abbott.
Any second Exact Sciences layoff round announced post-integration. Would signal Abbott managing for margin over growth.
CMS or major payer coverage decision on blood-based multi-cancer screening tests. Would show whether reimbursement parity is shifting toward Guardant Shield or GRAIL Galleri.
Key numbers
  • Abbott closed $21B all-cash buyout at $105/share (2026-03-23)
  • Q2 2026 Cancer Diagnostics revenue $919M, +13% (2026-07-16)
  • FY2025 revenue $3.25B, net loss $208M (2026-02-13)
Named risks
  • Abbott integration strain from $20B debt raise and EPS cut could limit Exact pipeline funding. Severity: high
  • Cologuard growth could fall below guided mid-teens in H2 2026 amid tough comps. Severity: high
  • Headcount reporting gap (7,200 vs 4,833) suggests possible undisclosed restructuring. Severity: medium
  • Blood-based competitors like Guardant Shield could erode stool-test-decliner segment. Severity: medium
  • CMS coverage parity decisions for blood-based screening could shift reimbursement economics. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
GRAIL (Galleri)contestingHolds ~70% MCED market share as of March 2025, though PATHFINDER 2 sensitivity data drew scrutiny
Guardant Health (Shield)contestingFDA-approved blood-based CRC test since 2024 competes for patients declining stool-DNA testing
Natera (Signatera)contestingLeads MRD monitoring market as of March 2026, challenging Exact's Oncodetect
Freenomegaining onRaised over $250M in late 2024 to fund Sandpiper multi-omics study
Questions people ask
Is Exact Sciences still a publicly traded company?
No. Abbott Laboratories completed its acquisition of Exact Sciences on March 23, 2026, paying $105 per share in cash for roughly $21 billion in equity value. Exact now operates as a standalone-managed subsidiary inside Abbott's Cancer Diagnostics business under Jake Orville, per Abbott's Q1 2026 earnings summary dated April 15, 2026.
Is Exact Sciences profitable?
Not on a GAAP basis. For full-year 2025, Exact Sciences reported a net loss of $208 million despite revenue of $3.25 billion, though adjusted EBITDA improved to $400 million, up $77 million year-over-year, according to its February 13, 2026 earnings release.
Who owns Exact Sciences now?
Abbott Laboratories owns Exact Sciences outright after closing a roughly $21 billion equity acquisition ($105/share cash, ~$23B enterprise value) on March 23, 2026. Exact continues to run its Cologuard and Cancerguard business inside Abbott's Cancer Diagnostics segment.
Could AI replace Cologuard or Exact Sciences' cancer tests?
Unlikely soon. Cologuard and Cologuard Plus carry FDA clearance, Medicare coverage, and American Cancer Society guideline endorsement reaffirmed in May 2026, a regulatory and reimbursement gauntlet AI labs cannot bypass. AI feeds interpretation within Exact's tests but cannot legally ship a competing diagnostic without trials and FDA approval.
Is Exact Sciences laying off workers?
Yes, at least once: in August 2025 Exact Sciences cut about 4% of its global workforce, roughly 200 Wisconsin positions including 80 at its Madison HQ and 120 remote roles, despite posting record revenue growth that quarter, per WPR reporting dated August 7, 2025.
Who is Exact Sciences' biggest competitor?
Guardant Health's Shield, an FDA-approved blood-based colorectal cancer screening test cleared in 2024, competes directly for patients who decline stool-DNA or colonoscopy testing. GRAIL's Galleri also contests the multi-cancer detection space, holding an estimated 70% MCED market share as of March 2025.
Timeline
  • 2026-07-17Abbott CEO Ford says deal model targets mid-teens Cologuard growth with stronger H2 2026
  • 2026-07-16Abbott Q2 2026 Cancer Diagnostics segment hits $919M, 13% comparable growth, Cologuard mid-teens
  • 2026-05-01American Cancer Society reaffirms Cologuard/Cologuard Plus as preferred CRC screening options
  • 2026-04-16Abbott cuts 2026 EPS guidance to $5.38-5.58 after $20B debt raise for Exact deal
  • 2026-04-15Abbott Q1 2026 results show double-digit growth from Cologuard/Cancerguard
  • 2026-03-23Abbott completes ~$21B acquisition of Exact Sciences at $105/share
  • 2026-02-26Exact Sciences shareholders approve Abbott acquisition
  • 2026-02-13Exact Sciences reports FY2025 revenue $3.25B, Q4 revenue $878M, net loss $208M
  • 2025-11-20Abbott announces definitive agreement to acquire Exact Sciences for $105/share
  • 2025-08-07Exact Sciences cuts about 200 Wisconsin jobs, 4% of global workforce
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources